松龄血脉康胶囊联合低剂量厄贝沙坦治疗65岁以上高血压患者疗效观察

Songlingxuemaikang capsule combined with low dose irbesartan treatment efficacy of hypertensive patients over the age of 65

目的观察松龄血脉康胶囊联合低剂量厄贝沙坦治疗65岁以上老年高血压病患者的临床疗效。方法将90例65岁以上高血压患者随机分为松龄血脉康胶囊联合低剂量厄贝沙坦治疗组和高剂量厄贝沙坦对照组。治疗组给予松龄血脉康胶囊1.5g,每天3次,同时加厄贝沙坦75mg/d;对照组单纯给予厄贝沙坦150mg/d治疗。两组治疗周期为1个月进行比较血压控制情况及不良反应等指标水平。结果治疗后,两组患者收缩压和舒张压均较治疗前下降,差异有统计学意义(P<0.05);治疗后两组患者的收缩压、舒张压比较,差异无统计学意义(P>0.05)。结论松龄血脉康联合低剂量厄贝沙坦治疗高血压疗效确切,无明显不良反应,值得临床应用。

Objective This study is to observe the clinical effect of songlingxuemaikang capsule combined with low dose of irbesartan in treatment over the age of 65 Elderly Patients with hypertension.Methods The songlingxuemaikang capsule combined with low dose irbesartan group 75 mg/d and control group 150 mg/d high dose irbesartan for 90 cases of hypertension patients were randomly divided over the age of 65,the control group only 150 mg/d irbesartan treatment,experimental group except songlingxuemaikang capsule 1.5 g TID 75 mg/d Jiae irbesartan treatment,the treatment period is 1 months comparison of two groups of blood pressure control and adverse reaction index.Results After 4 weeks of follow-up,the systolic blood pressure and diastolic blood pressure of the patients in the two groups were significantly lower than those before treatment,the difference was statistically significant （P〈0.05）.There was no significant difference between the two groups in systolic blood pressure and diastolic blood pressure （P〉0.05）.Conclusion Songling xuemai CMG with the efficacy of low dose of irbesartan in treatment of hypertension is effective,no obvious adverse reactions,and can reduce the dosage of irbesartan in clinic,so the two were combined with the clinical application in a more safe and effective.